Related Experiment Video
Updated: Mar 25, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Daptomycin for Children in Clinical Practice Experience
Silvia Garazzino1, Elio Castagnola, Maria Di Gangi
1From the *Department of Paediatrics, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, Italy; †Infectious Diseases Unit and Laboratory of Microbiology (RB), Istituto Giannina Gaslini, Genoa, Italy; ‡Malattie Infettive Pediatriche, Ospedale dei Bambini "G.Di Cristina"-A.R.N.A.S. Palermo, Palermo, Italy; §Department of Sciences for Health promotion and Mother and Child Care "Giuseppe D'Alessandro," University of Palermo, Palermo, Italy; ¶Department of Paediatric Medicine, Paediatric and Infectious Diseases Unit, Children Hospital Bambino Gesù, IRCCS, Rome, Italy; ‖Department of Paediatrics, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia," Udine, Italy; **Paediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ††University Department of Paediatrics, Unit of Immune and Infections Disease, Bambino Gesu' Children's Hospital, Rome Italy; and ‡‡Department of Sciences for Woman and Child's Health, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy.
Daptomycin is generally well-tolerated in children, even for extended periods. This study found few adverse events in pediatric patients receiving daptomycin treatment.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Therapeutics
Background:
- Limited data exist regarding daptomycin's efficacy and safety in pediatric populations.
- Daptomycin is a lipopeptide antibiotic used for Gram-positive bacterial infections.
Purpose of the Study:
- To evaluate the safety and tolerability of intravenous daptomycin in children.
- To assess daptomycin's use in a real-world pediatric clinical setting.
Main Methods:
- A multicenter, retrospective study was conducted.
- Data from 46 children treated with intravenous daptomycin were analyzed.
- Mean dosage was 7.0 mg/kg/d for a median of 14 days.
Main Results:
- Three children experienced adverse events potentially linked to daptomycin.
- The antibiotic was generally well-tolerated across the study cohort.
- Prolonged treatment durations did not appear to increase adverse event rates.
Conclusions:
- Intravenous daptomycin demonstrates a favorable safety profile in pediatric patients.
- Daptomycin can be considered a viable treatment option for Gram-positive infections in children.
- Further prospective studies could confirm these findings.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

